TLRY Tilray Brands, Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1731348 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.9%
TTM net income YoY92.4%
TTM EPS YoY94.2%
Revenue 3-yr CAGR14.0%
Net income 3-yr CAGR—
Margins
Gross margin29.1%
Operating margin-9.3%
Net margin-17.1%
FCF margin—
EBITDA margin—
Returns
ROE-10.4%
ROA-7.4%
ROIC (approx.)-5.0%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets31.0%
Debt / equity0.08x
Current ratio1.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.51x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-05-31 | FY20252025-05-31 |
|---|---|---|
| Income statement | ||
| Revenue | $915.45M | $821.31M |
| Cost of revenue | $655.01M | $580.74M |
| Gross profit | $260.44M | $240.57M |
| R&D expense | $361,000 | $284,000 |
| SG&A expense | $203.63M | $167.32M |
| Operating income | -$63.03M | -$2.28B |
| Interest expense | $29.91M | $41.33M |
| Pretax income | -$88.06M | -$2.30B |
| Income tax | $17.10M | -$121.02M |
| Net income | -$121.40M | -$2.19B |
| EPS (basic) | -1.09 | -24.56 |
| EPS (diluted) | -1.09 | -24.56 |
| Weighted avg. shares (diluted) | 111.83M | 89.03M |
| Balance sheet | ||
| Cash & equivalents | $225.98M | $221.67M |
| Short-term investments | $5.29M | $34.70M |
| Receivables | $189.17M | $121.49M |
| Inventory | $301.19M | $270.88M |
| Current assets | $792.13M | $688.63M |
| PP&E, net | $680.23M | $568.43M |
| Goodwill | $752.35M | $752.35M |
| Intangibles | $42.78M | $21.42M |
| Total assets | $2.33B | $2.07B |
| Current liabilities | $358.38M | $280.30M |
| Short-term debt | $8.78M | $7.18M |
| Long-term debt | $120.42M | — |
| Total debt | $129.20M | — |
| Total liabilities | $733.14M | $584.75M |
| Shareholders' equity | $1.61B | $1.51B |
| Net debt | -$96.78M | — |
| Shares outstanding | 131.68M | 106.07M |
| Cash flow statement | ||
| Operating cash flow | -$69.14M | -$94.60M |
| Capital expenditure | — | $32.92M |
| Free cash flow | — | -$127.52M |
| Investing cash flow | -$55.80M | -$46.72M |
| Financing cash flow | $130.99M | $133.51M |
| Stock-based compensation | $45.94M | $24.29M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.